New Study: Telehealth Is a Breakthrough for HIV Prevention
Nineteen percent of U.S. PrEP users received care through MISTR’s telehealth platform between 2018 and 2025, according to an...
A Breakthrough In Alcoholism Treatment: Clearmind Soars
Clearmind’s Phase I/IIa program for CMND-100 in alcohol use disorder has cleared an early safety gate: after dosing the...
Salarius, Texas Biomedical to Collaborate on Avian Flu Study
No clinical or in vitro efficacy data were reported. Decoy Therapeutics’ peptide conjugate influenza fusion inhibitors have only shown...
ORIC Pharma to Present Enozertinib Data in NSCLC at ESMO
ORIC will present Phase 1b data for enozertinib (ORIC-114), a selective, brain-penetrant EGFR/HER2 inhibitor, in previously treated HER2 exon...
Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
In a Phase 2 subgroup of mild-to-moderate Alzheimer’s disease, zervimesine (CT1812) was associated with a 95% slowing of cognitive...
Tokenization and Real-World Data Linkage: A New Era in Patient-Centric Trials
At the 2025 Indegene Digital Summit, a session hosted by Indegene and Datavant, senior leaders Mayank Rizada and Melissa...
Building a Scalable Clinical Foundation at Intercept Pharmaceuticals
At the Veeva R&D Summit, we spoke with Bill Wallace, CIO of Intercept Pharmaceuticals, about the company’s work to...
Vaxil Announces Update on Non-Brokered Private Placement
Vaxil Bio revised a planned financing to raise up to $350,000 via a non-brokered private placement of 3,111,111 units...
Junshi’s JS001SC Meets Phase 3 Endpoints for Lung Cancer
Non-squamous NSCLC patients treated first line with subcutaneous toripalimab plus chemotherapy achieved non-inferior drug exposure to intravenous toripalimab plus...
Praxis Reveals New Epilepsy Portfolio Data at AES Meeting
Praxis is taking a late-breaker slot at AES 2025 to unveil full results from RADIANT, reporting rapid seizure reductions...